肺癌
计算机科学
生物加工
癌症
间变性淋巴瘤激酶
医学
生物医学工程
病理
组织工程
内科学
恶性胸腔积液
作者
Mian Wang,Wanlu Li,Regina Sanchez Flores,Ling Cai,Carlos Ezio Garciamendez‐Mijares,Scott Gill,David W. Snyder,Jasmine Millabas,David Chafin,Yu Shrike Zhang,Azita Djalilvand
出处
期刊:Tissue Engineering Part A
[Mary Ann Liebert]
日期:2023-11-06
卷期号:30 (11-12): 270-279
被引量:1
标识
DOI:10.1089/ten.tea.2023.0149
摘要
Developing a reproducible and secure supply of customizable control tissues that standardizes for the cell type, tissue architecture, and preanalytics of interest for usage in applications including diagnostic, prognostic, and predictive assays, is critical for improving our patient care and welfare. The conventionally adopted control tissues directly obtained from patients are not ideal because they oftentimes have different amounts of normal and neoplastic elements, differing cellularity, differing architecture, and unknown preanalytics, in addition to the limited supply availability and thus associated high costs. In this study, we demonstrated a strategy to stably produce tissue-mimics for diagnostics purposes by taking advantage of the three-dimensional (3D) bioprinting technology. Specifically, we take anaplastic lymphoma kinase-positive (Alk+) lung cancer as an example, where a micropore-forming bioink laden with tumor cells was combined with digital light processing-based bioprinting for developing native-like Alk+ lung cancer tissue-mimics with both structural and functional relevancy. It is anticipated that our proposed methodology will pave new avenues for both fields of tissue diagnostics and 3D bioprinting significantly expanding their capacities, scope, and sustainability.
科研通智能强力驱动
Strongly Powered by AbleSci AI